Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

4.3%

1 terminated out of 23 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

43%

10 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed with results

Key Signals

3 with results92% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (2)
P 1 (1)
P 3 (7)
P 4 (3)

Trial Status

Completed11
Unknown5
Active Not Recruiting3
Recruiting3
Terminated1

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT00246857RecruitingPrimary

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

NCT04581460CompletedPrimary

Primitive Immunodeficiency and Pregnancy

NCT04784364Recruiting

Biologics And Clinical Immunology Cohort at Sinai

NCT04640142Phase 3Active Not RecruitingPrimary

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

NCT04702243Completed

Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults

NCT04919018Completed

Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies

NCT04565015Phase 3Active Not RecruitingPrimary

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

NCT05321407Active Not Recruiting

COVID-19 Vaccine Responses in PIDD Subjects

NCT04459689RecruitingPrimary

COVID-19 in PID Survey

NCT06014463CompletedPrimary

Evaluation of Adult Patients With Immunodeficiency Within the Scope of the ICF

NCT05932316Not ApplicableUnknown

Evaluating Bronchodilator Response in Patients With Bronchiectasis

NCT05070455Phase 4UnknownPrimary

An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

NCT05476653Not ApplicableUnknownPrimary

A Prospective Monocentric Study to Assess the Concordance of Lung MRI Compared to Chest CT Scan to Assess the Extent and Severity of Bronchial and Parenchymal Pulmonary Lesions in Adult Patients With Primary Immune Deficiency (PID) .

NCT00023504Phase 4TerminatedPrimary

Antibody Production in Immune Disorders

NCT03836690Phase 1Unknown

Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation

NCT02711228Phase 4CompletedPrimary

Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

NCT02868333UnknownPrimary

Determinants of Health Status and Quality of Life in Patients With Primary Immunodeficiencies Inhereted Diagnosed During Childhood

NCT01199705Phase 3CompletedPrimary

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

NCT01461018Phase 3CompletedPrimary

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

NCT00719680Phase 3CompletedPrimary

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Scroll to load more

Research Network

Activity Timeline